In the last trading session, 1,709,390 Altimmune, Inc. (NASDAQ:ALT) shares changed hands as the company’s beta touched 1.63. With the company’s per share price at $15.98 changed hands at $0.12 or 0.01% during last session, the market valuation stood at $613.58 Million. ALT’s last price was a discount, traded about -119.65% off its 52-week high of $35.1. The share price had its 52-week low at $7.8, which suggests the last value was 51.19% up since then. When we look at Altimmune, Inc.’s average trading volume, we note the 10-day average is 5.11 Million shares, with the 3-month average coming to 1.36 Million.
Analysts gave the Altimmune, Inc. (ALT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.7. If we narrow down to specifics, the data shows that none out of 7 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended ALT as a Hold, 7 felt it is a Buy and none rated the stock as Underweight. Altimmune, Inc.’s EPS for the current quarter is expected to be -$0.49.
Altimmune, Inc. (NASDAQ:ALT) trade information
Instantly ALT was in green as seen at the end of in last trading. With action 0.76%, the performance over the past five days has been green. The jump to weekly highs of $19.46 on Wednesday, Jun 16 added 17.88% to the stock’s daily price. The company’s shares are showing year-to-date upside of 0.42%, with the 5-day performance at 0.11% in the green. However, in the 30-day time frame, Altimmune, Inc. (NASDAQ:ALT) is 0.14% up. Looking at the short shares, we see there were 4.23 Million shares sold at short interest cover period of 3.11 days.
The consensus price target for the stock as assigned by Wall Street analysts is $44.29, meaning bulls need an upside of 177.16% from its current market value. According to analyst projections, ALT’s forecast low is $24 with $80 as the target high. To hit the forecast high, the stock’s price needs a +400.63% upsurge from its current level, while the stock would need to tank 50.19% for it to hit the projected low.
Altimmune, Inc. (ALT) estimates and forecasts
Data shows that the Altimmune, Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot +30.24% over the past 6 months, a 37.7% in annual growth rate that is considerably higher than the industry average of 16.4%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Altimmune, Inc. will rise +47.9%, while the growth in revenue is estimated to hit -1.9% for the next quarter. Year-over-year growth is forecast to reach -1.6% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $3.01 Million. 6 analysts are of the opinion that Altimmune, Inc.’s revenue for the quarter ending September 01, 2021 will be $3.18 Million. The company’s revenue for the corresponding quarter a year ago was $1.1 Million. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 173.6%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.7%. The 2021 estimates are for Altimmune, Inc. earnings to decrease by -19.7%, but the outlook for the next 5-year period is at 0% per year.
Altimmune, Inc. (NASDAQ:ALT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.23% of Altimmune, Inc. shares while 62.57% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 66.72%. There are 120 institutions holding the Altimmune, Inc. stock share, with VR Adviser, LLC the top institutional holder. As of Mar 30, 2021, the company held 9.12% of the shares, roughly 3.5 Million ALT shares worth $49.46 Million.
State Street Corporation holds the second largest percentage of outstanding shares, with 7.66% or 2.94 Million shares worth $41.57 Million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Apr 29, 2021 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Smallcap World Fund. With 3069012 shares estimated at $44.41 Million under it, the former controlled 7.99% of total outstanding shares. On the other hand, Smallcap World Fund held about 3.66% of the shares, roughly 1.4 Million shares worth around $19.84 Million.